Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF)

Digestive and Liver Disease

Volumn 46, Issue 1, 2014, Pages 18-24

  Coco, Barbara ^a   Caraceni, Paolo ^a   Aghemo, Alessio ^b   Bitetto, Davide ^b   Bruno, Raffaele ^b   Ciancio, Alessia ^a   Marzioni, Marco ^a   Petta, Salvatore ^b   Rendina, Maria ^a   Valenti, Luca ^a  

^a AISF Coordinating Committee ^*  (Italy)

^b AISF Consulting Committee on the New Antiviral Hepatitis C Drugs   (Italy)

Author keywords

Boceprevir; Cirrhosis; Hepatitis C; Pegylated interferon; Ribavirin; Telaprevir

Indexed keywords

BOCEPREVIR; PROTEINASE INHIBITOR; TELAPREVIR;

ALGORITHM; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL DECISION MAKING; CRYOGLOBULINEMIA; DRUG TREATMENT FAILURE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER GRAFT; MEDICAL SOCIETY; MIXED INFECTION; NONHUMAN; PATIENT SELECTION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; REVIEW;

BOCEPREVIR; CIRRHOSIS; HEPATITIS C; PEGYLATED-INTERFERON; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL AGENTS; DRUG CARRIERS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RIBAVIRIN;

EID: 84892373565     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.08.243     Document Type: Review

References (47)

1. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. The New England Journal of Medicine 2011, 364:1207-1217.
2. Hezode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England Journal of Medicine 2009, 360:1839-1850.
3. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine 2011, 364:2405-2416.
4. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
5. McHutchison J.G., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic HCV infection. The New England Journal of Medicine 2010, 362:1292-1303.
6. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. The New England Journal of Medicine 2011, 364:1195-1206.
7. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. The New England Journal of Medicine 2011, 365:1014-1024.
8. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. The New England Journal of Medicine 2011, 364:2417-2428.
9. EASL clinical practice guidelines: management of hepatitis C virus infection. Journal of Hepatology 2011, 55:245-264. European Association for the Study of the Liver.
10. Ghany M.G., Nelson D.R., Strader D.B., et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
11. The Italian Association for the Study of the Liver (AISF) The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease 2013, [in press].
12. Bruno S., Stroffolini T., Colombo M., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007, 45:579-587.
13. Jacobson I.M., Davis G.L., El-Serag H., et al. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clinical Gastroenterology and Hepatology 2010, 8:924-933.
14. Jacobson I.M., Catlett I., Marcellin P., et al. Telaprevir substantially improved SVR rates accross all IL28B genotypes in the ADVANCE trial. Journal of Hepatology 2011, 54:S543.
15. McHutchison J.G., Lawitz E.J., Shiffman M.L., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. The New England Journal of Medicine 2009, 361:580-593.
16. Pol A., Aerssen J., Zeuzem S., et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial or null-responder patients treated with telaprevir/peg-IFN/ribavirin: retrospective analysis of the REALIZE study. Journal of Hepatology 2011, 54:S6.
17. Thompson A.J., Muir A.J., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virological response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139:120-129.
18. Fried M.W., Hadziyannis S.J., Shiffman M.L., et al. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Journal of Hepatology 2011, 55:69-75.
19. Poordad F., Bronowicki J.P., Gordon S.C., et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012, 143:608-618.
20. Bruno S., Shiffman M.L., Roberts S.K., et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010, 51:388-397.
21. Cheng W.S., Roberts S.K., McCaughan G., et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. Journal of Hepatology 2010, 53:616-623.
22. Bruno S., Vierling J.M., Esteban R., et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. Journal of Hepatology 2013, 58:479-487.
23. Bronowicki J.P., Davis M., Flamm S., et al. Sustained virological response (SVR) in prior peginterferon/ribavirin (PR) treatment failure after retreatment with boceprevir + PR: the PROVIDE study interim results. Journal of Hepatology 2012, 56:S611.
24. Foster G.R., Zeuzem S., Andreone P., et al. Sustained virological response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. Journal of Hepatology 2013, 58:488-494.
25. Agency EM. Victrelis [Boceprevir]. In: Accessed: 17 August 2011. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/002332/human_med_001464.jsp.
26. Agency EM. Incivo [Telaprevir] In: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_product_Information/human/002313/WC500115529.pdf.
27. Bacon B.R., Bruno S., Schiff E.R., et al. Predictors of Sustained Virological Response (SVR) among poor Interferon (IFN) responders when Boceprevir (BOC) is added to Peginterferon Alfa-2b/Ribavirin (PR). Hepatology 2011, 54:33A.
28. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
29. Zeuzem S., Pooard F., Gordon S.C., et al. Boceprevir resistance-associated variants (RAVS) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alfa-2b/ribavirin. Journal of Hepatology 2011, 54:S8.
30. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
31. Hezode C., Dorival C., Zoulim F., et al. Safety and efficacy of telaprevir and boceprevir in combination with peginterferon alfa/ribavirin in 497 cirrhotic non responders: week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. Hepatology 2012, 56:S51.
32. Maasoumy B., Port K., Markova A.A., et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 2013, 8:e55528.
33. Colombo M., Andreone P.A., Babudieri P.S., et al. Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the Italian telaprevir early access program. Digestive and Liver Disease 2013, 45:OC-26.
34. Salmon-Ceron D., Rosenthal E., Lewden C., et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study. Journal of Hepatology 2009, 50:736-745.
35. Macias J., Berenguer J., Japon M.A., et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009, 50:1056-1063.
36. Rodriguez-Torres M., Slim J., Bhatti L., et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clinical Trials 2012, 13:142-152.
37. Sulkowski M., Pol S., Cooper C., et al. Boceprevir+pegylated interferon+ribavirin for the treatment of HCV/HIV-coinfected patients: end of treatment (week 48) interim results. 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), March 5-8 2012, [abstract 47].
38. Sulkowski M.S., Sherman K.E., Soriano V., et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR24 final study results. Hepatology 2012, 56:54A.
39. Berenguer M., Prieto M., Rayon J.M., et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000, 32:852-858.
40. Roche B., Sebagh M., Canfora M.L., et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transplantation 2008, 14:1766-1770.
41. Verna E.C., Burton J.R., O'Leary J.G., et al. A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipient: report from the CRUSH-C group. Journal of Hepatology 2013, 58(Suppl. 1):S10.
42. Lilly L., Selzner N., Levy G., et al. High rates of undetectable HCV RNA in liver transplant recipients treated with protease inhibitor-based antiviral therapy for recurrent hepatitis C. Journal of Hepatology 2013, 58(Suppl. 1):S75.
43. Coilly A., Dumortier J., Botta-Fridlund D., et al. End of treatment response after protease inhibitor (PI)-based therapy for hepatitis C recurrence after liver transplantation: a multicenter European experience. Journal of Hepatology 2013, 58(Suppl. 1):S572.
44. Hulskotte E., Gupta S., Xuan F., et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012, 56:1622-1630.
45. Garg V., van Heeswijk R., Lee J.E., et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011, 54:20-27.
46. Triboli E., Fabbrizzi A., Monti M., et al. Boceprevir triple therapy in patients with mixed cryoglobulinemia. Digestive and Liver Disease 2013, 45:OC28.
47. Burger D., Back D., Buggisch P., et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. Journal of Hepatology 2012, 58:792-800.